|Year : 2016 | Volume
| Issue : 1 | Page : 49-53
Quality of life among human immunodeficiency virus-1 infected and human immunodeficiency virus-1/hepatitis C virus co-infected individuals in Iranian patients
Sarah Sabouri1, Ali Delavar1, Hossain Jabbari2
1 Department of Psychology and Educational Sciences, University of Allameh Tabataba'i, Tehran, Iran
2 Department of Infectious Diseases, ian Research Center for HIV/AIDS, Tehran University of Medical Sciences;Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
|Date of Web Publication||15-Apr-2016|
Department of Infectious Diseases, Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Tehran
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: The aim of this study was to compare the quality of life (QOL) of people infected with both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). The study design was a cross sectional descriptive survey, using self administered questionnaires. Materials and Methods: A convenience sample of 242 patients (131 of them HIV/HCV), Iranian adults (aged 18–57) living with HIV/AIDS, was recruited from outpatient referring to Imam Khomeini Hospital behavioral counseling center in Tehran city, Iran. The instruments included the Multidimensional QOL HIV (MQoL HIV) and a demographic section. Results: The majority of the samples were male and single. The mean age was 36.52 years (standard deviation = 8.5). HIV mono infected patients reported higher scores in social support and physical functioning, but lower scores in physical health compared with HIV/HCV co infected individuals. There was no significant difference in overall MQOL HIV score between HIV and HIV/HCV patients. Conclusion: Future studies will need to explore the impact of HCV on HIV infected individuals' QOL.
Keywords: Co-infected, hepatitis C virus, human immunodeficiency virus
|How to cite this article:|
Sabouri S, Delavar A, Jabbari H. Quality of life among human immunodeficiency virus-1 infected and human immunodeficiency virus-1/hepatitis C virus co-infected individuals in Iranian patients. Niger Med J 2016;57:49-53
|How to cite this URL:|
Sabouri S, Delavar A, Jabbari H. Quality of life among human immunodeficiency virus-1 infected and human immunodeficiency virus-1/hepatitis C virus co-infected individuals in Iranian patients. Niger Med J [serial online] 2016 [cited 2020 Aug 3];57:49-53. Available from: http://www.nigeriamedj.com/text.asp?2016/57/1/49/180560
| Introduction|| |
Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is one of the significant public health problems around the world.,, HIV and HCV share the same routes of transmission. Both viruses can be transmitted through exposure to contaminated blood, sexual intercourse, and from mother to child. In Europe, the United States and Australia, approximately 25% of people living with HIV (PLHIV) are co-infected with HCV, however, HCV prevalence differs based on the route through which HIV has been acquired. The highest HCV co-infection rates are among persons who have acquired HIV from injection drug use, where the rates reach almost 30–50% or even more among this population.,,, According to the 2010 update of the UNAIDS/World Health Organization (WHO) epidemiological fact sheet (“Update of the UNAIDS/WHO epidemiological fact sheet,” 2010), the estimated number of PLHIV/AIDS in Iran is 80,000. Therefore, it can be estimated that at least about 20,000–40,000 of those individuals have HIV/HCV infection at the same time.
Health-related quality of life (HRQOL) is recognized as a significant factor in the assessment of burden in chronic diseases. HCV has frequently been reported as a factor associated with a poor HRQOL in immunocompetent patients., The results of studies involved with HRQOL of HIV-infected individuals show that HIV is also associated with reduced HRQOL;, however, it has been found that better QOL is associated with the absence of mental illness, social support, and also fewer years as a nonintravenous drug user, not being an intravenous drug user, not having any difficulty in taking the medication, and being female.
The impact of HIV/HCV co-infection on QOL is studied since before.,,, Furthermore, HRQOL of Iranian PLHIV/AIDS is studied using WHO QOL for HIV/AIDS. By our knowledge, this study is the first one to compare the QOL of mono-infected HIV and co-infected HIV/HCV in a substantial number of patients living with HIV/AIDS in the Middle East and North Africa region.
| Materials and Methods|| |
This was a cross-sectional study comprising patients visited the Imam Khomeini Hospital behavioral counseling center conducted over a 1-year period since May 2009–March 2010. The study participants were 242 PLHIV, of them 131 participants were co-infection with HIV and HCV. The study was approved by the Institutional Review Board of Tehran University of Medical Sciences. Before enrollment to the study, written informed consent was taken from participants. Multidimensional QOL Questionnaire for HIV/AIDS (MQOL-HIV) was implemented. The MQOL-HIV is a multidimensional, 40-item instrument that purports to measure ten dimensions of QOL specific to PLHIV. These include mental health, physical functioning, physical health, social support, social functioning, cognitive functioning, financial status, partner intimacy, sexual functioning, and medical care. Each of these dimensions is measured by four items. Each item is worded as a statement and is prefaced by a question, “How often (have) each of these statements been true for you in the past 2 weeks” response options range from “1: Never” through “7: Always.” Separate domain scores can be obtained by summing the frequency of the four items in each domain, with a possible range of 4–28. In addition to QOL scores for each domain, a single summary index for overall QOL was computed using the mental health and physical functioning domain scores. For individual domain scores and the summary index score, a low score represented poor QOL and vice versa.
Translation into Farsi and standardization of this questionnaire was done by Sh. in Iran. Inclusion criteria comprised a diagnosis of HIV infection, age of 18, no severe cognitive impairments such as AIDS dementia complex, and any physiologic disabilities such as hearing impairments and mental disabilities.
Demographic characteristics were calculated using Student's t-tests to compare the mean MQOL-HIV subscale scores of Iranian HIV alone and HIV/HCV co-infected patients. The study's sample of HIV/HCV was based on patient's records. Results are expressed as means, percentages, standard deviations, and standard errors of means. The internal consistency of the subscales of the MQOL-HIV was assessed by Cronbach's alpha. The Chi-square analysis for categorical data and Student's t-test or ANOVA with Tukey's test for multiple comparisons were performed to identify factors associated with the MQOL-HIV scores of both groups of HIV/HCV co-infected and HIV mono-infected participants.
| Results|| |
Of the 214 participants, 131 were HIV/HCV co-infected and 83 were HIV mono-infected. Mean age was 36.52 (range: 18–57) years. The majority of the sample belonged to age category of 31–40 years (42.9%). Patients co-infected with HIV/HCV were more likely to be male (173 [80.8%] vs. 41 [19.2%]), infected via drug injection (128 [60.7%]) and alcohol consumer and had history of drug use, cigarette smoking, and needle sharing, 145 (69%), 154 (73%), and 133 (62.1%), respectively, Majority of the participants were single 85 (39.7%), married 83 (38.8%), and 10.7% divorced. Educational levels were neither high nor low, with 74 (34.6%) secondary school, 64 (30%) elementary school, 58 (27.1%) precollege schooling grades, and 14 (6.5%) had university degrees. 72 (33.8%) of participants were unemployed, 71 (33.3%) involved in nongovernment-based jobs, and 32 (15%) engaged in home duties. Around half (104 [52.3%]) of participants' CD4 counts were between 200 and 500 cells/μL. 102 participants (approximately 48%) reported that their income rate was “very low” (<1000, 000 Rails); also, regarding for source of income, majority of patients (96 [46.2%]) reported they have no regular income source. In terms of transmission mode and alcohol intake, over 70% (143) of PLHIV did not use alcohol at all; however, some of them (44 [21.6%]) drink [Table 1] and [Table 2].
|Table 2: Distribution and reliability of multidimensional quality of life--human immunodeficiency virus subscales|
Click here to view
| Discussion|| |
In this study, HRQOL of 131 HIV/HCV co-infected participants was investigated and compared to 83 HIV mono-infected participants.
Although there are evidence that HRQOL diminishes in patients infected with HCV or HIV alone, there is a paucity of data to show the effect of HIV/HCV co-infection on HRQOL. The overall mean scores of MQOL-HIV demonstrated no significant difference in both HIV/HCV co-infected and HIV mono-infected participants (134.84 ± 26.80 vs. 11.58 ± 2.55, P ≤ 0.270).
The relatively same mean scores in the overall score is in line with the results from Kanwal et al. study in 2005 who reported no significant differences in disease burden among HIV mono- and HIV/HCV or HIV/HBV co-infected participants using a generic HRQOL instrument, this could be explained by the finding that most of the patients with HCV infection usually are asymptomatic until the advanced stages of the disease, and so HIV/HCV co-infection does ensue to a total change in the course of diseases.
In domains analyses, our study results showed that QOL scores were lower in the physical health (13.48 ± 3.10 vs. 12.20 ± 4.68; P ≤ 0.032), physical functioning (14.32 ± 4.69 vs. 16.10 ± 4.81; P ≤ 0.008), and social support (12.88 ± 4.85 vs. 14.31 ± 5.13; P ≤ 0.040) domains in HIV/HCV co-infected participants compared to those with HIV mono-infection. These findings are similar to the results reported by Baum et al. which was done on 218 HIV positive drug users, and also results of the study performed by Tillmann et al. Furthermore, significant lower mean scores in the domain of physical functioning was reported by Tsui et al., however, the results of the mean scores in the domain of social functioning, in this study differs from the results of Tsui et al., who found that HIV/HCV participants report lower mean scores. Whether these findings in domains analyses are a direct effect or an indirect effect of HCV superinfection on HIV infection, needs more investigations and scrutiny. In this study, the rate of cigarette smoking reported in participants with HIV/HCV co-infection (113 [53.6%]) was much higher than those with HIV (41 [19.4%]). This finding is similar to the results reported by Balfour et al. on cigarette smoking, and its independent association with reduced health-related QOL scores  Alcohol consumption rate reported by participants with HIV/HCV co-infection was also higher than those with HIV mono-infection. These results are consistent with results achieved the study conducted by Zani et al., who found a fairly high proportion of HCV-infected patients who regularly drink alcohol and coffee beverages and smoke cigarettes, especially among males.
In this study, the histories of alcohol intake, drug use, and sharing needle of PLHIV/HCV also were significantly higher than those with HIV mono-infection. The low scores of the physical health and physical functioning domains can thus be attributed to alcohol intake theoretically. Excess alcohol consumption with therapy for HIV infection increases HCV RNA levels and may impede the effectiveness of this treatment strategy, there was no clear explanation to show these differences in risky behaviors (cigarette smoking and alcohol consumption) between the study groups. This issue needs further investigations.
The high number of HCV infection found in our study among HIV-infected participants is due to injection drug use, as the dominant route of HIV transmission. This subpopulation of PLHIV is usually of lower socioeconomic status and literacy. This situation, and specially the later one, could behave as a limiting factor of this study to take precise answer from participants. The strength of the study, however, is that none of the patients were under HCV treatment with pegylated interferon, which affects patients' feelings and their QOL.
| Conclusion|| |
In summary, patients with HIV mono-infection and HIV/HCV co-infection have similar perceptions of their HRQOL total scores. However, in domains analyses, such perceptions are significantly lower in physical health, physical functioning, and social support domains in HIV/HCV co-infected participants compared to those with HIV mono-infection. Our data underscore the impact of complex medical and psychosocial issues on HRQOL and indicate the need for a multidisciplinary approach to improve HRQOL in HIV and/or HCV care settings.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al.
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
Buti M, Wong J, Casado MA, Esteban R. Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. J Hepatol 2006;44 1 Suppl: S60-4.
Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004;5:174-9.
Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: Cure and control, right now. J Int AIDS Soc 2011;14:22.
SeyedAlinaghi S, Jam S, Mehrkhani F, Fattahi F, Sabzvari D, Kourorian Z, et al.
Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. Acta Med Iran 2011;49:252-7.
Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected Person. Ann Intern Med 2003;138:197-207.
Langohr K, Sanvisens A, Fuster D, Tor J, Serra I, Rey-Joly C, et al.
Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients. Open AIDS J 2008;2:82-8.
Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299-301.
Silvestri F, Barillari G, Fanin R, Salmaso F, Pipan C, Falasca E, et al.
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma. Ann Oncol 1998;9:499-504.
Préau M, Marcellin F, Carrieri MP, Lert F, Obadia Y, Spire B; VESPA Study Group. Health-related quality of life in French people living with HIV in 2003: Results from the national ANRS-EN12-VESPA Study. AIDS 2007;21 Suppl 1:S19-27.
Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: Measurement by the medical outcomes study instrument. Ann Intern Med 1992;116:129-37.
Ruiz Perez I, Rodriguez Baño J, Lopez Ruz MA, del Arco Jimenez A, Causse Prados M, Pasquau Liaño J, et al.
Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors. Qual Life Res 2005;14:1301-10.
Fleming CA, Christiansen D, Nunes D, Heeren T, Thornton D, Horsburgh CR Jr., et al.
Health-related quality of life of patients with HIV disease: Impact of hepatitis C coinfection. Clin Infect Dis 2004;38:572-8.
Gillis J, Cooper C, Rourke S, Rueda S, O'Brien K, Collins E, et al.
Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals. Qual Life Res 2013;22:1525-35.
Braitstein P, Montessori V, Chan K, Montaner JS, Schechter MT, O'Shaughnessy MV, et al.
Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: Outcomes from a population-based cohort. AIDS Care 2005;17:505-15.
Thein H, Maruff P, Krahn M, Kaldor J, Koorey DJ, Brew B, et al.
Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Med 2007;8:192-202.
Razavi P, Hajifathalian K, Saeidi B, Esmaeeli Djavid G, Rasoulinejad M, Hajiabdolbaghi M, et al.
Quality of life among persons with HIV/AIDS in Iran: Internal reliability and validity of an international instrument and associated factors. AIDS Res Treat 2012;2012:849406.
Smith KW, Avis NE, Mayer KH, Swislow L. Use of the MQoL-HIV with asymptomatic HIV-positive patients. Qual Life Res 1997;6:555-60.
Moradi Sh, Wiese-Fayyaz O. “Quality of life and its associated factors in a sample of HIV infected women in Tehran city”. Family Research Magazine 2007;8:309-25.
Kanwal F, Gralnek IM, Hays RD, Dulai GS, Spiegel BM, Bozzette S, et al.
Impact of chronic viral hepatitis on health-related quality of life in HIV: Results from a nationally representative sample. Am J Gastroenterol 2005;100:1984-94.
Baum MK, Jayaweera DT, Duan R, Sales S, Lai S, Rafie C, et al.
Quality of life, symptomatology and healthcare utilization in HIV/HCV co-infected drug users in Miami. J Addict Dis 2008;27:37-48.
Tillmann HL, Kaiser T, Claes C, Schmidt RE, Manns MP, Stoll M. Differential influence of different hepatitis viruses on quality of life in HIV positive patients. Eur J Med Res 2006;11:381-5.
Tsui JI, Bangsberg DR, Ragland K, Hall CS, Riley ED. The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV. AIDS Behav 2007;11:603-10.
Balfour L, Cooper C, Kowal J, Tasca GA, Silverman A, Kane M, et al.
Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C. Can J Gastroenterol 2006;20:81-6.
Zani C, Donato F, Chiesa M, Baiguera C, Gelatti U, Covolo L, et al.
Alcohol and coffee drinking and smoking habit among subjects with HCV infection. Dig Liver Dis 2009;41:599-604.
Cooper CL, Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis 2005;41 Suppl 1:S105-9.
[Table 1], [Table 2]
|This article has been cited by|
||Clinical determinants associated with quality of life for people who live with HIV/AIDS: a Meta-analysis
| ||Hesam Ghiasvand,Katherine M. Waye,Mehdi Noroozi,Gholamreza Ghaedamini Harouni,Bahram Armoon,Azadeh Bayani |
| ||BMC Health Services Research. 2019; 19(1) |
|[Pubmed] | [DOI]|
||Impacts of GRIN3A, GRM6 and TPH2 genetic polymorphisms on quality of life in methadone maintenance therapy population
| ||Ruey-Yun Wang,Hsiu-Ju Chen,Chieh-Liang Huang,Jiun-Yi Wang,Tsui-Er Lee,Hsiang-Yen Lee,Chin-Chuan Hung,Weihua YUE |
| ||PLOS ONE. 2018; 13(7): e0201408 |
|[Pubmed] | [DOI]|